Pharmacology of the antifungals used in the treatment of aspergillosis
Azanza JR [SP] (1), Sádaba B [SP] (2), Gómez-Guíu A (2).
(1) Servicio de Farmacología Clínica, Clínica universidad de Navarra, Pamplona, España.
(2) Servicio de Farmacología Clínica, Clínica universidad de Navarra, Pamplona, España.
Magazine: Revista Iberoamericana de Micología
Date: Dec 1, 2014Clinical Research Unit [SP] Clinical Pharmacology [SP]
The treatment of invasive aspergillosis requires the use of drugs that characteristically have complex pharmacokinetic properties, the knowledge of which is essential to achieve maximum efficacy with minimal risk to the patient.
The lipid-based amphotericin B formulations vary significantly in their pharmacokinetic behaviour, with very high plasma concentrations of the liposomal form, probably related to the presence of cholesterol in their structure. Azoles have a variable absorption profile, particularly in the case of itraconazole and posaconazole, with the latter very dependent on multiple factors. This may also lead to variations in voriconazole, which requires considering the possibility of monitoring plasma concentrations.
The aim of this article is to review some of the most relevant aspects of the pharmacology of the antifungals used in the prophylaxis and treatment of the Aspergillus infection. For this reason, it includes the most relevant features of some of the azoles normally prescribed in this infection (itraconazole, posaconazole and voriconazole) and the amphotericin B formulations.
CITATION Rev Iberoam Micol. 2014 Oct-Dec;31(4):255-61. doi: 10.1016/j.riam.2014.05.001
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.